TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to First Grade 3 or 4 Hematological Toxicity or Liver Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Seroma formation at donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achievement of target TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety and efficacy of propofol
Endpoint domain: Adverse events/effects
Primary endpoint: Diastolic strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acoustic reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loudness discomfort level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in INR value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variations in OAT weekly dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time assessed by the difference in using the umbilicus method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications that occur in using the umbilicus method
Endpoint domain: Adverse events/effects
Primary endpoint: Coordination of the surgeon movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fasting plasma glucose (FPG) mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycated hemoglobin A1c (HbA1c) %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Bicarbonate:lactate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin Hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Red Spot Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of participants with a complete response of no emetic episode
Endpoint domain: Adverse events/effects
Primary endpoint: Number of acute angioedema attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Curve (AUC(0 to Infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction of standardized patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Montgomery Asberg Depression Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Hamilton Rating Scale for Anxiety (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary composite efficacy endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-Life (t1/2) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative analysis of muscle involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IPSS changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading speeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health-related quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: long-term cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Reporting a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Fluoroscopy time of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiation dose absorbed by the patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of chronic lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of immune markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fat fraction difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Global evaluation of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score of subjective image quality of CT image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants on Tocilizumab Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VAS pain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of risperidone treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with in-hospital VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to MMT Initiation Post Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Risk Behaviors - Self Report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delayed Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clearance (CL) of Pantoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Distribution (Vd) of Pantoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Tolerability - First Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Local Tolerability - Second Dose
Endpoint domain: Adverse events/effects
Primary endpoint: number of women who used modern, reversible contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of women who had postnatal care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of women whose infants had immunizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain scores using the verbal rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction rate of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluation of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to obtain gastric smooth muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall impact of fibromyalgia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Score for Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total Score for Speed of Processing (i.e., Cognition)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma levels of Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive and negative symptom scales (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The repeatable battery for the assessment of neuropsychological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Insight and Treatment Attitudes Questionnaire (ITAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in cough symptomology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Remission with clearance of Minimal Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Pancreatic Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hospital admissions for any cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: COVID-19 incidence and prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of the Estimated 10-year Total Cardiovascular Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious Adverse Event Incidence Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Behaviors of Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Compliance for coronary heart disease secondary prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants who Experience any of the Pre-Specified Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 counts > 200/uL or recovery of CD4 > 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caries Extension According to Diagnocam Codes 0-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC post prandial glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of complete necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of carotid plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of perception distortions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of neutrophil and platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of immune reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trabecular bone volume at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in sleep/wake architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in Liver Phospho-EGFR Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Were Progression Free at 2 Months
Endpoint domain: Mortality/survival
Primary endpoint: ALP level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EASI score decline rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute and subacute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve of Plasma Concentration of Drug From Time 0 to t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration of Drug Through Time (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-life (T1/2_Kel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in depression post treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Vaginal Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Cesarean Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak nasal inspiratory flow (PNIF) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of KMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Zarit Burden Interview (ZBI)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change From Baseline Center for Epidemiological Studies-Depression (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With IGA 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Small and large bowel transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Seropositivity rates for anti-PCV-1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates for anti-PCV-1 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in HERO Wellness Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days to ANC Greater Than or Equal to 1,000/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary assisted patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time in glycemic target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: admission to the intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readmission to the hospital because of COPD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total Hydrocodone Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical metrics of tactile responsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of a new medium of communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of occurred adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Elderly oral care-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude toward elderly oral care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy of elderly oral care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intention to elderly oral care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: exhaled nitric oxide change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Use Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in strength of the deep cervical musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neurofunctional deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Symptoms and Medication Score (CSMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of arterial carbon dioxide pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients without major amputation
Endpoint domain: Mortality/survival
Primary endpoint: Peak Plasma Concentration (Cmax) of Aripiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve 168h (AUC168h) of Aripiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Score of Symbol Digit Modalities Test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Client treatment retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the SNAC plasma concentration-time curve (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed SNAC plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLU-AUC 0:30-4:30h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: All cause morbidity within the first 7 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural damage in Rheumatoid Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression of obesity associated NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of CDK, CCP, PLK
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: count of peripheral blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma area under the curve (AUC) of cefazolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Volume of Carotid Arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Human Anti-Human Antibodies (HAHAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hours of HME Use Per Day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Device Preference Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in AQLQ(S) overall scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Who Experienced Psoriasis Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Communication Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Management Composite
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EuroQol, EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in depression/anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Freedom from neuroma recurrence evaluated by physical exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from neuroma recurrence evaluated by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Statewide awareness (level of knowledge and detection)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cancer data collection (correlation with demographic and geographic factors)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reach of educational campaign
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: emotion regulation (DERS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropeptide Y (NPY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fear potentiated startle data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent diameter stenosis of the analysis segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving ACR20 Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: End of Week 12 weekly mean pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of the signs of body fluid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from enrollment to cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Beausang's scar scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin elasticity (Cutometer®)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin moisture (Corneometer®)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change score of FACT-L scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bioequivalence AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in JASPER Strategy Implementation Fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes